These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25656013)

  • 1. [Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation].
    Wada N; Okazaki S; Kobayashi S; Hashizume K; Kita M; Matsumoto S; Kakizaki H
    Hinyokika Kiyo; 2015 Jan; 61(1):7-11. PubMed ID: 25656013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Video-urodynamic effects of mirabegron, a β3 -adrenoceptor agonist, in patients with low-compliance bladder.
    Kamei J; Furuta A; Akiyama Y; Niimi A; Ichihara K; Fujimura T; Fukuhara H; Kume H; Homma Y; Igawa Y
    Int J Urol; 2015 Oct; 22(10):956-61. PubMed ID: 26177781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study.
    Park JS; Lee YS; Lee CN; Kim SH; Kim SW; Han SW
    World J Urol; 2019 Aug; 37(8):1665-1670. PubMed ID: 30511212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction.
    Welk B; Hickling D; McKibbon M; Radomski S; Ethans K
    Neurourol Urodyn; 2018 Nov; 37(8):2810-2817. PubMed ID: 30168626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury.
    Wada N; Shimizu T; Takai S; Shimizu N; Tyagi P; Kakizaki H; Yoshimura N
    Neurourol Urodyn; 2017 Apr; 36(4):1039-1045. PubMed ID: 27367752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.
    Wöllner J; Pannek J
    Spinal Cord; 2016 Jan; 54(1):78-82. PubMed ID: 26503222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
    Zachariou A; Filiponi M; Baltogiannis D; Giannakis J; Dimitriadis F; Tsounapi P; Takenaka A; Sofikitis N
    Can J Urol; 2017 Dec; 24(6):9107-9113. PubMed ID: 29260636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction.
    Sager C; Sanmartino M; Burek C; Gomez YR; Vazquez Patiño M; Weller S; Ruiz J; Lopez Imizcoz F; Tessi C; Szklarz T; Corbetta JP
    J Pediatr Urol; 2020 Oct; 16(5):655.e1-655.e6. PubMed ID: 32800710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review.
    Akkoc Y
    Spinal Cord; 2022 Oct; 60(10):854-861. PubMed ID: 36085413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum injection is useless on fibrotic neuropathic bladders.
    Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
    J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-Life Data on Mirabegron in Neurogenic Bladder Dysfunction.
    Soebadi MA; Hakim L; Van der Aa F; De Ridder D
    Urol Int; 2019; 103(2):195-201. PubMed ID: 31096260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of mirabegron in neurogenic bladder: a systematic review.
    El Helou E; Labaki C; Chebel R; El Helou J; Abi Tayeh G; Jalkh G; Nemr E
    World J Urol; 2020 Oct; 38(10):2435-2442. PubMed ID: 31802206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurogenic bladder in patients with traumatic spinal cord injury: treatment and follow-up.
    ; Yıldız N; Akkoç Y; Erhan B; Gündüz B; Yılmaz B; Alaca R; Gök H; Köklü K; Ersöz M; Cınar E; Karapolat H; Catalbaş N; Bardak AN; Turna I; Demir Y; Güneş S; Alemdaroğlu E; Tunç H
    Spinal Cord; 2014 Jun; 52(6):462-7. PubMed ID: 24732167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and safety of sacral neuromodulation on neurogenic bladder and bowel dysfunction in patients with spina bifida].
    Chen G; Wang Y; Ying X; Pang D; Liao L
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2021 Nov; 35(11):1374-1379. PubMed ID: 34779161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for neurogenic detrusor overactivity.
    Chancellor MB; Anderson RU; Boone TB
    Am J Phys Med Rehabil; 2006 Jun; 85(6):536-45. PubMed ID: 16715024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The place of mirabegron in clinical practice].
    Kasyan GR; Sukhikh SO; Pushkar DY
    Urologiia; 2017 Dec; (6):144-148. PubMed ID: 29376612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detrusor overactivity in spina bifida: how long does it need to be treated?
    Ab E; Dik P; Klijn AJ; van Gool JD; de Jong TP
    Neurourol Urodyn; 2004; 23(7):685-8. PubMed ID: 15382196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report.
    Kato T; Mizuno K; Nishio H; Yasui T; Hayashi Y
    J Med Case Rep; 2021 Feb; 15(1):86. PubMed ID: 33602290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.